| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1999PNAS...96.8639B |
| P356 | DOI | 10.1073/PNAS.96.15.8639 |
| P932 | PMC publication ID | 17569 |
| P698 | PubMed publication ID | 10411928 |
| P5875 | ResearchGate publication ID | 12887394 |
| P50 | author | John Dick | Q6229356 |
| Edus H Warren | Q37842175 | ||
| P2093 | author name string | S R Riddell | |
| D Bonnet | |||
| P D Greenberg | |||
| P2860 | cites work | Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell | Q27861001 |
| A cell initiating human acute myeloid leukaemia after transplantation into SCID mice | Q28131777 | ||
| Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group | Q28296408 | ||
| Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. | Q30179443 | ||
| A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. | Q30274634 | ||
| Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein | Q30464516 | ||
| Bone-marrow transplantation (first of two parts). | Q34649003 | ||
| Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes | Q35752628 | ||
| Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. | Q36175538 | ||
| Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes | Q36230215 | ||
| Bone-marrow transplantation (second of two parts). | Q38091044 | ||
| Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts | Q39244446 | ||
| Graft-versus-leukemia following bone marrow transplantation | Q39702530 | ||
| Structure, organization, and sequence of alpha satellite DNA from human chromosome 17: evidence for evolution by unequal crossing-over and an ancestral pentamer repeat shared with the human X chromosome | Q40667149 | ||
| The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. | Q41061835 | ||
| Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity | Q41110821 | ||
| Graft-versus-leukemia reactions after bone marrow transplantation | Q41198977 | ||
| Allogeneic hematopoietic stem cell transplantation for acute leukemia. | Q41358223 | ||
| Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy | Q41561713 | ||
| Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation | Q44233640 | ||
| In vivo migration and function of transferred HIV-1-specific cytotoxic T cells | Q47995100 | ||
| Identical-twin bone marrow transplants for leukemia. | Q53383868 | ||
| Identification of a graft versus host disease-associated human minor histocompatibility antigen | Q56929110 | ||
| Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens | Q59394048 | ||
| Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens | Q67898770 | ||
| Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation | Q68191397 | ||
| Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients | Q68640720 | ||
| Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms | Q69490654 | ||
| Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation | Q70149552 | ||
| Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft-versus-host disease status and analyses of tissue distribution of their target antigens | Q70656738 | ||
| Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia | Q71017497 | ||
| Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients | Q72009940 | ||
| Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones | Q72249189 | ||
| Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation | Q73117300 | ||
| Human cytotoxic CD8+ T-lymphocyte clones engraft in severe combined immunodeficient (SCID) mice but show diminished function | Q73190937 | ||
| Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution | Q74270437 | ||
| Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia | Q77052799 | ||
| Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation | Q77549838 | ||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| cytotoxicity | Q246181 | ||
| acute myeloid leukemia | Q264118 | ||
| P304 | page(s) | 8639-8644 | |
| P577 | publication date | 1999-07-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells | |
| P478 | volume | 96 |
| Q24536117 | A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia |
| Q34815702 | A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy. |
| Q24657877 | ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome |
| Q92337111 | Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia |
| Q35570287 | Adoptive Immunotherapy in Chimeras with Donor Lymphocytes |
| Q37268297 | Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia |
| Q41791126 | Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model |
| Q34279672 | Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation |
| Q37795965 | An Overview of Concepts for Cancer Stem Cells |
| Q34564542 | An antigen produced by splicing of noncontiguous peptides in the reverse order. |
| Q91707889 | An in silico-in vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients |
| Q34312702 | Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors |
| Q24539030 | Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission |
| Q33437907 | Association of IL-10 and IL-10Rbeta gene polymorphisms with graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling donor |
| Q36662079 | Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation |
| Q34452706 | Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy? |
| Q36177214 | CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model |
| Q36764900 | Cancer stem cells--an old idea that's new again: implications for the diagnosis and treatment of breast cancer |
| Q35772708 | Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches |
| Q38015268 | Concise review: the role of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia |
| Q34243434 | Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen |
| Q36591409 | DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells |
| Q51028658 | Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. |
| Q37832506 | Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation |
| Q34124707 | Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation |
| Q34163218 | Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia |
| Q33854489 | Gene therapy of pediatric leukemia. |
| Q33290423 | Graft-versus-host disease: a surge of developments |
| Q34253590 | Haematopoietic cell transplantation as immunotherapy |
| Q34571817 | Haemopoietic stem-cell transplantation: recent progress and future promise |
| Q34089112 | Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy |
| Q35035740 | Human NK cells and their receptors. |
| Q81632634 | Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice |
| Q63386801 | Immune recovery in children undergoing allogeneic stem cell transplantation: absolute CD8+CD3+ count reconstitution is associated with survival |
| Q33943241 | Immunity to stemness genes in human cancer |
| Q38003477 | Immunotherapeutic approaches to improve graft-versus-tumor effect and reduce graft-versus-host disease |
| Q38171574 | Immunotherapy in acute myeloid leukemia |
| Q39205106 | Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel? |
| Q37763280 | Immunotherapy prospects for acute myeloid leukaemia |
| Q34926682 | Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods |
| Q40629220 | In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation |
| Q36490755 | Induction of tumor immunity following allogeneic stem cell transplantation |
| Q34214817 | Leukemia vaccines |
| Q33931811 | Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells |
| Q30412320 | MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. |
| Q24529145 | Mammary stem cells, self-renewal pathways, and carcinogenesis |
| Q39249452 | Minor histocompatibility antigen UTY as target for graft-versus-leukemia and graft-versus-haematopoiesis in the canine model |
| Q36830199 | Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions. |
| Q35214671 | Minor histocompatibility antigens in human stem cell transplantation |
| Q39564229 | Mismatched human leukocyte antigen class II-restricted CD8⁺ cytotoxic T cells may mediate selective graft-versus-leukemia effects following allogeneic hematopoietic cell transplantation. |
| Q34318010 | Molecules and mechanisms of the graft-versus-leukaemia effect |
| Q82884856 | NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic |
| Q83186138 | NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic |
| Q74675080 | NK cells: a lesson from mismatched hematopoietic transplantation |
| Q34319345 | Non-MHC-restricted cytotoxic cells: their roles in the control and treatment of leukaemias |
| Q34298262 | Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation |
| Q37461365 | Novel strategies for improved cancer vaccines |
| Q52881816 | Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index. |
| Q50708752 | Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice. |
| Q35181654 | Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission |
| Q36769053 | Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes |
| Q37461075 | Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells. |
| Q34065058 | Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited |
| Q24642254 | Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation |
| Q36581381 | Sustained disease-free survival achieved with withdrawal of immunosuppression after rapid relapse of myelodysplastic syndrome following myeloablative allogeneic hematopoietic transplantation: a case report |
| Q34608658 | T-cell therapy of leukemia. |
| Q35578576 | Targeting Alloreactive Donor T-Cells to Hematopoietic System-Restricted Minor Histocompatibility Antigens to Dissect Graft-versus-Leukemia Effects from Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation |
| Q36994811 | Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses |
| Q37242262 | Targets of tumor immunity after allogeneic hematopoietic stem cell transplantation |
| Q35158955 | The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. |
| Q24296246 | The human cathepsin H gene encodes two novel minor histocompatibility antigen epitopes restricted by HLA-A*3101 and -A*3303 |
| Q38073107 | The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation. |
| Q44574754 | The progenitor cell inhibition assay to measure the anti-leukemic reactivity of T cell clones against acute and chronic myeloid leukemia. |
| Q34117982 | The prospects for cancer gene therapy. |
| Q37543431 | The role of oral beclometasone dipropionate in the treatment of gastrointestinal Graft-versus-Host Disease |
| Q37460362 | The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor |
| Q33849560 | Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens |
| Q73758095 | Tissue-restricted T cell alloresponses across HLA barriers: selection and identification of leukemia-restricted CTL in HLA-mismatched stimulator-responder pairs |
| Q37486793 | Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation |
| Q33398031 | Two host factors regulate persistence of H7-specific T cells injected in tumor-bearing mice |
| Q34285656 | Use of tumour-responsive T cells as cancer treatment |
| Q37939527 | Vaccines targeting cancer stem cells: are they within reach? |
| Q35166856 | WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies |
| Q36328410 | Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? |
Search more.